Posted on by admin

Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics

Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics
The Key Iron Deficiency Anemia Companies in the market include – MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others.

 

DelveInsight’s “Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Iron Deficiency Anemia, historical and forecasted epidemiology as well as the Iron Deficiency Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Iron Deficiency Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Iron Deficiency Anemia Market Forecast

 

Some of the key facts of the Iron Deficiency Anemia Market Report: 

  • The Iron Deficiency Anemia market size was valued approximately ~USD 1,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • DelveInsight reported that Oral Ferrous Products (OFPs) generated nearly USD 80 million in revenue across the 7MM in 2023. Among these products, ferrous sulfate accounted for the highest revenue during that year.

  • In February 2024, The new SANOIN clinical study, backed by P&G Health (the healthcare division of P&G) and carried out by top healthcare professionals, revealed that iron supplementation with Sangobion (ferrous gluconate combined with multivitamins and minerals) effectively enhances Hemoglobin (Hb) levels and quality of life (QOL), providing symptom relief. The study results indicated a notable increase in Hb levels within 14 days, symptom relief within 30 days, and improved QOL for women suffering from Iron Deficiency Anemia.

  • In 2023, the United States had approximately 9,510,600 prevalent cases.

  • In 2023, it was noted that Iron Deficiency Anemia was more common in females than in males, making up about 65% of the cases.

  • In 2023, iron deficiency anemia cases in the United States were predominantly attributed to iron deficiency anemia (IDA) and chronic kidney disease, which together represented approximately 30% of the cases by pathology.

  • Companies such as Akebia Therapeutics (Keryx Biopharmaceuticals) in collaboration with Japan Tobacco (through its subsidiary Torii Pharmaceutical) and Shield Therapeutics in partnership with Norgine BV have entered the Iron Deficiency Anemia (IDA) market. This market was previously dominated by over-the-counter (OTC) and prescription oral iron products (OFPs) as well as intravenous (IV) iron treatments. These companies aim to provide safer, more effective, and more convenient oral medications for IDA patients.

  • Key Iron Deficiency Anemia Companies: MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others

  • Key Iron Deficiency Anemia Therapies: MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others

  • The Iron Deficiency Anemia epidemiology based on gender analyzed that Iron Deficiency Anemia affects more females as compared to males

  • The Iron Deficiency Anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Iron Deficiency Anemia pipeline products will significantly revolutionize the Iron Deficiency Anemia market dynamics.

 

Iron Deficiency Anemia Overview

Iron Deficiency Anemia (IDA) is a common type of anemia that occurs when the body lacks enough iron to produce hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. Hemoglobin is crucial for delivering oxygen from the lungs to other parts of the body and for returning carbon dioxide from the tissues back to the lungs.

 

Get a Free sample for the Iron Deficiency Anemia Market Report: 

https://www.delveinsight.com/report-store/iron-deficiency-anemia-market

 

Iron Deficiency Anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Iron Deficiency Anemia Epidemiology Segmentation:

The Iron Deficiency Anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Iron Deficiency Anemia

  • Prevalent Cases of Iron Deficiency Anemia by severity

  • Gender-specific Prevalence of Iron Deficiency Anemia

  • Diagnosed Cases of Episodic and Chronic Iron Deficiency Anemia

 

Download the report to understand which factors are driving Iron Deficiency Anemia epidemiology trends @ Iron Deficiency Anemia Epidemiology Forecast

 

Iron Deficiency Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Iron Deficiency Anemia market or expected to get launched during the study period. The analysis covers Iron Deficiency Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Iron Deficiency Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Iron Deficiency Anemia Therapies and Key Companies

  • MPB-1514 (IOP Injection): MegaPro Biomedical

  • IDAX (IHAT-02): Nemysis

  • Ferric Derisomaltose: Pharmacosmos A/S

  • ferric citrate: Keryx Biopharmaceuticals

  • iron isomaltoside 1000 (Monofer®): Pharmacosmos A/S

  • Ferric carboxymaltose: Tigermed Consulting Co., Ltd

  • Ferric Maltol: Shield Therapeutics

  • Z-213: Zeria Pharma

  • KER-047: Keros Therapeutics, Inc.

  • Ferumoxytol: AMAG Pharma

  • venoferrum(iron sucrose): JW Pharmaceutical

  • Z-213: Zeria Pharma

 

Discover more about therapies set to grab major Iron Deficiency Anemia market share @ Iron Deficiency Anemia Treatment Market

 

Iron Deficiency Anemia Market Drivers

  • Increasing changes in lifestyle

  • Increasing cases of anemia

  • Growth in geriatric population

 

Iron Deficiency Anemia Market Barriers

  • Extensive usage of over-the-counter (OTC) medications

  • Availability of generics

  • Lack of robust pipeline

 

Scope of the Iron Deficiency Anemia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Iron Deficiency Anemia Companies: MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others

  • Key Iron Deficiency Anemia Therapies: MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others

  • Iron Deficiency Anemia Therapeutic Assessment: Iron Deficiency Anemia current marketed and Iron Deficiency Anemia emerging therapies

  • Iron Deficiency Anemia Market Dynamics: Iron Deficiency Anemia market drivers and Iron Deficiency Anemia market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Iron Deficiency Anemia Unmet Needs, KOL’s views, Analyst’s views, Iron Deficiency Anemia Market Access and Reimbursement 

 

To know more about Iron Deficiency Anemia companies working in the treatment market, visit @ Iron Deficiency Anemia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Iron Deficiency Anemia Market Report Introduction

2. Executive Summary for Iron Deficiency Anemia

3. SWOT analysis of Iron Deficiency Anemia

4. Iron Deficiency Anemia Patient Share (%) Overview at a Glance

5. Iron Deficiency Anemia Market Overview at a Glance

6. Iron Deficiency Anemia Disease Background and Overview

7. Iron Deficiency Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Iron Deficiency Anemia 

9. Iron Deficiency Anemia Current Treatment and Medical Practices

10. Iron Deficiency Anemia Unmet Needs

11. Iron Deficiency Anemia Emerging Therapies

12. Iron Deficiency Anemia Market Outlook

13. Country-Wise Iron Deficiency Anemia Market Analysis (2020–2034)

14. Iron Deficiency Anemia Market Access and Reimbursement of Therapies

15. Iron Deficiency Anemia Market Drivers

16. Iron Deficiency Anemia Market Barriers

17.  Iron Deficiency Anemia Appendix

18. Iron Deficiency Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/